Q/C Technologies Receives Nasdaq $1.00 Bid Deficiency Notice, 180 Days to Cure
QCLS is trading near its 52-week low of $0.301 (1.7% above the low).
Summary
Q/C Technologies received a Nasdaq notice on November 6, 2026 that its stock has traded below $1.00 for 30 consecutive business days, giving it until May 5, 2027 to regain compliance or face delisting.
Key Events · Legal and Risk Events · QCLS
-
Nasdaq Bid Price Deficiency Notice
Nasdaq notified the company on November 6, 2026 that its closing bid price had fallen below the $1.00 minimum under Listing Rule 5550(a)(2) for the 30 consecutive business days from September 25 to November 5, 2026.
-
180-Day Cure Window to May 5, 2027
The company has until May 5, 2027 to regain compliance. A further 180 days is available only if it meets the market value of publicly held shares and all other initial listing standards apart from bid price.
-
Reverse Split Named as Possible Cure
According to the filing, the company could cure the deficiency during a second compliance period by effecting a reverse stock split if necessary; no split has been announced or approved.
-
No Assurance of Regaining Compliance
The company says it is evaluating options and intends to regain compliance, but states there can be no assurance it will do so or remain in compliance with other Nasdaq continued listing requirements.
Analysis · QCLS · Life Sciences
A Nasdaq deficiency letter received November 6 puts Q/C Technologies on the clock: the stock closed below $1.00 for 30 straight business days, from September 25 to November 5, 2026. Regaining compliance means getting the bid back above $1.00 by May 5, 2027. A second 180-day window is available only if the company meets the market value of publicly held shares and other initial listing standards, and a reverse split is explicitly named as a possible cure. For a company already carrying going-concern warnings and a $100M shelf, this adds a listing deadline on top of a cash problem. A reverse split would likely be the path, and that resets the share price without fixing the underlying business. Failure to cure ends in delisting.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QCLS was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.30 to $8.17. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.